VETOQUINOL SA (VETO.PA) Stock Price, Forecast & Analysis

Europe Euronext Paris EPA:VETO • FR0004186856

88.6 EUR
+1.7 (+1.96%)
Last: Feb 2, 2026, 09:07 AM

VETO.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.05B
Revenue(TTM)532.39M
Net Income(TTM)60.08M
Shares11.88M
Float3.81M
52 Week High87.8
52 Week Low68.1
Yearly Dividend0.85
Dividend Yield1.05%
EPS(TTM)5.04
PE17.58
Fwd PE17.07
Earnings (Next)03-18
IPO2006-11-16
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
VETO.PA short term performance overview.The bars show the price performance of VETO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

VETO.PA long term performance overview.The bars show the price performance of VETO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20

The current stock price of VETO.PA is 88.6 EUR. In the past month the price increased by 2.96%. In the past year, price increased by 22.39%.

VETOQUINOL SA / VETO Daily stock chart

VETO.PA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to VETO.PA. When comparing the yearly performance of all stocks, VETO.PA is one of the better performing stocks in the market, outperforming 84.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VETO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to VETO.PA. VETO.PA has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VETO.PA Financial Highlights

Over the last trailing twelve months VETO.PA reported a non-GAAP Earnings per Share(EPS) of 5.04. The EPS increased by 26.53% compared to the year before.


Industry RankSector Rank
PM (TTM) 11.28%
ROA 8.28%
ROE 10.59%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%5.9%
Sales Q2Q%-2.57%
EPS 1Y (TTM)26.53%
Revenue 1Y (TTM)-0.95%

VETO.PA Forecast & Estimates

11 analysts have analysed VETO.PA and the average price target is 92.41 EUR. This implies a price increase of 4.3% is expected in the next year compared to the current price of 88.6.


Analysts
Analysts80
Price Target92.41 (4.3%)
EPS Next Y0%
Revenue Next Year-1.84%

VETO.PA Ownership

Ownership
Inst Owners12.36%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About VETO.PA

Company Profile

VETO logo image Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte and currently employs 2,497 full-time employees. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

Company Info

VETOQUINOL SA

Sainte-Anne 34 rue du Chene, Bp 189, Lure Cedex

Lure BOURGOGNE-FRANCHE-COMTE FR

Employees: 2519

VETO Company Website

VETO Investor Relations

Phone: 33384625555

VETOQUINOL SA / VETO.PA FAQ

What does VETO do?

Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte and currently employs 2,497 full-time employees. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.


What is the current price of VETO stock?

The current stock price of VETO.PA is 88.6 EUR. The price increased by 1.96% in the last trading session.


Does VETOQUINOL SA pay dividends?

VETOQUINOL SA (VETO.PA) has a dividend yield of 1.05%. The yearly dividend amount is currently 0.85.


What is the ChartMill technical and fundamental rating of VETO stock?

VETO.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is VETOQUINOL SA (VETO.PA) stock traded?

VETO.PA stock is listed on the Euronext Paris exchange.


Can you provide the market cap for VETOQUINOL SA?

VETOQUINOL SA (VETO.PA) has a market capitalization of 1.05B EUR. This makes VETO.PA a Small Cap stock.


When does VETOQUINOL SA (VETO.PA) report earnings?

VETOQUINOL SA (VETO.PA) will report earnings on 2026-03-18, after the market close.